FDA approves first drug for infantile spasms

Aug 21, 2009

(AP) -- The Food and Drug Administration has approved the first drug to treat infantile spasms, a rare disorder that can cause hundreds of seizures per day in children less than a year old.

Sabril is an oral solution from Deerfield, Ill.-based Lundbeck Inc. approved for children between the ages of 1 month and 2 years. Infantile spasms usually occur while babies are eating or waking up, and often come in clusters of up to 100.

FDA director of neurology products Russell Katz says: " in this young are very serious and this approval provides these patients and their parents a treatment option."

The FDA also approved a Sabril tablet to treat seizures in adults who have not responded to other drugs.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: New US restrictions on painkiller to take effect

add to favorites email to friend print save as pdf

Related Stories

Diet may eliminate spasms for infants with epilepsy

Sep 08, 2008

Infantile spasms are a severe and potentially devastating epilepsy condition affecting children aged typically 4-8 months. In a new study appearing in Epilepsia, researchers have found that the ketogenic diet, a high fat, l ...

FDA OKs Amitiza for treatment of IBS-C

Apr 30, 2008

The U.S. Food and Drug Administration announced approval of Amitiza (lubiprostone) to treat constipation associated with irritable bowel syndrome.

FDA OKs 50th & 51st anti-retroviral drugs

Aug 14, 2007

The U.S. Food and Drug Administration has tentatively approved nevirapine tablets and a pediatric medication used to treat the human immunodeficiency virus.

Recommended for you

New US restrictions on painkiller to take effect

7 hours ago

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

User comments : 0